肝脏 ›› 2022, Vol. 27 ›› Issue (2): 199-202.

• 肝癌 • 上一篇    下一篇

US-CT/MRI融合成像技术用于原发性肝癌精准射频治疗中的价值

王彬, 齐县伟, 张宪亮   

  1. 466000 河南 周口市中心医院介入治疗科
  • 收稿日期:2021-09-07 出版日期:2022-02-28 发布日期:2022-04-19
  • 通讯作者: 张宪亮,Email:zhangxian96168@163.com
  • 基金资助:
    河南省科技攻关项目(182102310093)

The value of US-CT/MRI fusion imaging technology in precision radiofrequency therapy of primary liver cancer

WANG Bin, QI Xian-wei, ZHANG Xian-liang   

  1. Department of interventional therapy,Zhoukou Central Hospital, Henan 466000, China
  • Received:2021-09-07 Online:2022-02-28 Published:2022-04-19
  • Contact: ZHANG Xian-liang,Email:zhangxian96168@163.com

摘要: 目的 研究超声-电子计算机断层扫描/磁共振(US-CT/MRI)融合成像技术用于原发性肝癌精准射频治疗中的价值。方法 选择2014年1月至2019年1月周口市中小医院收治的50例原发性肝癌患者作为研究对象,根据常规超声是否清晰显示病灶将其分为两组,超声显示困难的纳入观察组(19例),超声显示清晰的纳入对照组(31例)。观察组在射频消融术中使用US-CT/MRI融合成像进行引导,对照组在射频消融术中使用常规超声进行引导。记录两组完成射频消融、术中补充消融、术后完全消融情况,以及术后并发症发生情况和2年内生存率。结果 两组完成射频消融率分别为94.74%、100.00%,两组术中补充消融率分别为26.32%、3.23%,两组术后完全消融率分别为100.00%、93.55%。与对照组相比,观察组术中补充消融率较高,P<0.05,两组完成射频消融、术后完全消融情况无明显差异,P>0.05;治疗后2年内,观察组死亡3例(15.79%),对照组死亡6例(19.35%),两组2年内生存率无明显差异,P>0.05;两组术后并发症发生率分别为0、3.23%,两组术后并发症发生率无明显差异,P>0.05。结论 US-CT/MRI融合成像技术用于原发性肝癌精准射频治疗具有较高的完全消融率,安全性较好,对于常规超声显影比较困难的病灶,使用US-CT/MRI融合成像可清晰显影,临床应用价值较高。

关键词: 原发性肝癌, 射频消融, 超声检查, 电子计算机断层扫描, 磁共振成像, 融合成像

Abstract: Objective To investigate the value of US-CT /MRI fusion imaging in the precision radiofrequency (RF) therapy of primary liver cancer. Methods A total of 50 patients with primary liver cancer admitted from January 2014 to January 2019 were selected as the study subjects. According to whether the lesions were clearly displayed by conventional ultrasound, they were divided into the following two groups: 19 cases in the observation group with difficult ultrasound display, and 31 cases in the control group with clear ultrasound display. The observation group was guided by US-CT/MRI fusion imaging during RF ablation, while the control group was guided by conventional ultrasound during RF ablation. The completion of radiofrequency ablation, intraoperative supplementary ablation, postoperative complete ablation, postoperative complications, and 2-year survival rate were recorded in both groups. Results The completed RF ablation rates of the two groups were 94.74% and 100.00%, the intraoperative supplementary ablation rates of the two groups were 26.32% and 3.23%, and the postoperative complete ablation rates of the two groups were 100.00% and 93.55%, respectively. Compared with the control group, the observation group had a higher intraoperative supplementary ablation rate (P<0.05). There was no significant difference in completed RF ablation and postoperative complete ablation between the two groups (P>0.05). Within 2 years after treatment, 3 cases (15.79%) died in the observation group and 6 cases (19.35%) died in the control group. There was no significant difference in the 2-year survival rate between these two groups (P>0.05). The incidence of postoperative complications in these two groups was 0.00% and 3.23%, respectively. There was no significant difference in the incidence of postoperative complications between these two groups (P> 0.05). Conclusion US-CT/MRI fusion imaging has higher complete ablation rate and better safety in accurate radiofrequency ablation of primary liver cancer. For Lesions that are difficult to be detected by conventional ultrasound, US-CT/MRI fusion imaging can provide clear imaging thus has better clinical application value.

Key words: Primary liver cancer, Radiofrequency ablation, Ultrasonic examination, Computed tomography, Magnetic resonance imaging, Fusion imaging